58 patents
Utility
Cytotoxic and Anti-mitotic Compounds, and Methods of Using the Same
7 Dec 23
Compounds having cytotoxic and/or anti-mitotic activity are disclosed.
Geoffrey C. WINTERS, Alexander Laurence MANDEL, James R. RICH, Bradley John HEDBERG, Tom Han Hsiao HSIEH, Elyse Marie Josée BOURQUE, John BABCOOK
Filed: 21 Feb 23
Utility
Cytotoxic and Anti-mitotic Compounds, and Methods of Using the Same
5 Oct 23
Compounds having cytotoxic and/or anti-mitotic activity are disclosed.
Geoffrey C. WINTERS, James R. RICH, Graham Albert Edwin GARNETT, Alexander Laurence MANDEL, Tom Han Hsiao HSIEH, Elyse Marie Josée BOURQUE, Stuart Daniel BARNSCHER
Filed: 20 Jan 23
Utility
IMMUNOGLOBULIN Fc REGION VARIANTS COMPRISING STABILITY-ENHANCING MUTATIONS
28 Sep 23
Fc variants are described comprising one or more amino acid mutations that increase the stability of the Fc variant as compared to a parental Fc that does not include the one or more amino acid mutations, as well as polypeptides comprising an Fc variant and polynucleotides encoding an Fc variant.
Genevieve DESJARDINS, Eric ESCOBAR-CABRERA, Antonios SAMIOTAKIS, Gavin Carl JONES
Filed: 20 May 21
Utility
Cytotoxic and anti-mitotic compounds, and methods of using the same
4 Apr 23
Compounds having cytotoxic and/or anti-mitotic activity are disclosed.
Geoffrey C. Winters, Alexander Laurence Mandel, James R. Rich, Bradley John Hedberg, Tom Han Hsiao Hsieh, Elyse Marie Josée Bourque, John Babcook
Filed: 11 Feb 19
Utility
Cytotoxic and anti-mitotic compounds, and methods of using the same
28 Feb 23
Compounds having cytotoxic and/or anti-mitotic activity are disclosed.
Geoffrey C. Winters, James R. Rich, Graham Albert Edwin Garnett, Alexander Laurence Mandel, Tom Han Hsiao Hsieh, Elyse Marie Josée Bourque, Stuart Daniel Barnscher
Filed: 26 Jul 19
Utility
Anti-tissue Factor Antibody-drug Conjugates and Related Methods
18 Aug 22
Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs.
Jan-Willem Theunissen, Allen G. Cai, Thi-Sau Migone
Filed: 2 Jul 20
Utility
Modified Antigen Binding Polypeptide Constructs and Uses Thereof
11 Aug 22
The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof.
Mario SANCHES, Thomas Spreter Von Kreudenstein, Dunja Urosev, Stacey A.L. Tom-Yew, Adam Louis Corper, Igor Edmondo Paolo D'Angelo, Yang-Chieh Chou, Surjit Bhimarao Dixit
Filed: 25 Feb 22
Utility
Engineered Immunoglobulin Heavy Chain-light Chain Pairs and Uses Thereof
21 Jul 22
The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof.
Adam Louis CORPER, Dunja UROSEV, Stacey A.L. TOM-YEW, Dustin Weyland Blue BLEILE, Thomas SPRETER VON KREUDENSTEIN, Surjit DIXIT, Paula Irene LARIO, Mario SANCHES
Filed: 24 Jan 22
Utility
Anti-PD-L1-anti-TIM-3 bispecific antibodies
7 Jun 22
The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human TIM-3, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
Yiwen Li, Dale Lincoln Ludwig, Yang Shen, Yi Zhang, Igor Edmondo Paolo D'Angelo
Filed: 12 Mar 19
Utility
Bispecific antigen-binding constructs targeting Her2
10 May 22
Provided herein are biparatopic antigen-binding constructs that specifically bind HER2.
Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
Filed: 18 Jun 18
Utility
Methods of Using a Bispecific Antigen-binding Construct Targeting HER2 for the Treatment of Biliary Tract Cancers
5 May 22
Described herein is a method of treating biliary tract cancer (BTC) comprising administering a bispecific antigen-binding construct targeting HER2 or a bispecific antigen-binding construct targeting HER2 linked to an auristatin analogue (ADC) to a subject.
Diana F. Hausman, Neil C. Josephson, Rose Kamyee Lai, Gerald James Rowse, Patrick Kaminker
Filed: 19 Nov 21
Utility
Modified antigen binding polypeptide constructs and uses thereof
19 Apr 22
The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof.
Mario Sanches, Thomas Spreter Von Kreudenstein, Dunja Urosev, Stacey A. L. Tom-Yew, Adam Louis Corper, Igor Edmondo Paolo D'Angelo, Yang-Chieh Chou, Surjit Bhimarao Dixit
Filed: 29 May 15
Utility
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
29 Mar 22
The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof.
Adam Louis Corper, Dunja Urosev, Stacey A. L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
Filed: 5 Sep 18
Utility
Multivalent heteromultimer scaffold design and constructs
15 Feb 22
Provided herein are multifunctional heteromultimer proteins.
Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, Mario Sanches, Gordon Yiu Kon Ng
Filed: 21 May 19
Utility
Bispecific Antigen-binding Constructs Targeting HER2
30 Dec 21
Provided herein are biparatopic antigen-binding constructs that specifically bind HER2.
Nina E. Weisser, Gordon Yiu Kon NG, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
Filed: 24 Feb 21
Utility
Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof
28 Dec 21
The present disclosure provides light chain polypeptides that include a C-terminal extension, as well as antibodies and antibody conjugates containing such modified light chain polypeptides, where the C-terminal extension includes one or more cysteine residues.
John Babcook, James R. Rich, Jan Peter Bergqvist, Stuart Daniel Barnscher
Filed: 23 Dec 14
Utility
Antigen-Binding Constructs Targeting HER2
23 Dec 21
Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2.
Eric Escobar-Cabrera, Leonard G. Presta
Filed: 3 May 21
Utility
Checkpoint inhibitor bispecific antibodies
21 Dec 21
The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human PD-1, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
Michael Dewain Kalos, Yiwen Li, Dale Lincoln Ludwig, Yang Shen, Igor Edmondo Paolo D'Angelo, Gregory D Plowman
Filed: 9 Jul 18
Utility
ANTI-PD-1/LAG3 Bispecific Antibodies
2 Dec 21
Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments.
Laurence FAYADAT-DILMAN, Veronica JUAN, Shireen KHAN, Shaopeng HUANG, Hua YING, Eric Escobar CABRERA, Genevieve DESJARDINS
Filed: 23 Jul 21
Utility
ANTI-PD-1/LAG3 Bispecific Antibodies
25 Nov 21
Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments.
Laurence FAYADAT-DILMAN, Veronica JUAN, Shireen KHAN, Shaopeng HUANG, Hua YING, Eric Escobar CABRERA, Genevieve DESJARDINS
Filed: 23 Jul 21